Tenet Healthcare Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 23, 2025, reports the execution of an amended and restated employment agreement with Saumya Sutaria, M.D., the Company's Chief Executive Officer and Chairman of the Board. The agreement is effective as of January 23, 2025.
Key Financial Metrics
The filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
Material Changes and Compensation Terms
- Term: Initial term from January 23, 2025, to December 31, 2028, with automatic one-year extensions unless 180 days' notice is provided.
- Base Salary: Annualized base salary of $1,500,000.
- Annual Incentive: Target bonus of no less than 200% of base salary ($3,000,000).
- Signing/Retention Equity: $18 million in Restricted Stock Units (RSUs).
- 40% vests pro rata annually over four years (2025-2028).
- 60% is performance-based over a four-year period.
- Retirement Contribution: Annual contributions of at least $250,000 to an executive retirement account.
Severance and Change of Control Provisions
The agreement outlines significant severance packages triggered by termination without "cause" or resignation with "good reason":
- Outside Change of Control Window: (More than 6 months prior or 2 years post-change of control)
- 2.5x sum of base salary plus target bonus, paid over 2.5 years.
- Accelerated vesting of all unvested equity.
- 2.5 years of continued health coverage.
- Inside Change of Control Window: (Within 6 months prior or 2 years post-change of control)
- 3x sum of base salary plus target bonus, paid in a single lump sum.
- Accelerated vesting of all unvested equity.
- 3 years of continued health coverage.
- Death or Disability: Accelerated vesting of all unvested equity and pro-rata bonus.
- Expiration of Term: If Dr. Sutaria elects not to renew, unvested equity continues to vest for 2.5 years post-term.
Risks and Covenants
Dr. Sutaria is subject to perpetual confidentiality and non-disparagement covenants. Non-solicitation applies for the duration of employment plus two years. Non-competition applies to four primary competitors for the duration of employment plus one year.
Investor Verification Checklist
- Verify the specific performance metrics for the 60% performance-based RSUs, as they are determined by the HR Committee and not detailed in this summary.
- Review the full text of Exhibit 10.1 for precise definitions of "cause," "good reason," and "change of control."
- Assess the impact of the $18 million equity grant on future dilution and compensation expense recognition.
- Confirm the total potential payout in a change of control scenario, which could exceed $13.5 million in cash severance alone (3x $4.5M).